ALEC
$2.05-0.01 (-0.49%)
Alector, Inc., a late-stage clinical biotechnology company, develops therapies that is focused on counteracting the devastating progression of neurodegenerative diseases.
Recent News
Why The Narrative Around Alector (ALEC) Is Shifting With Its BBB Shuttle Focus
Alector’s latest analyst update moves its modeled fair value from US$2.10 to US$2.88, a shift that sits between a bullish US$6 target and a bearish US$0.90 view. Both sides are reacting to the same pivot toward BBB shuttle therapeutics, but while optimistic analysts see a clearer, more focused story, cautious voices still emphasize execution risk and past trial setbacks. As you read on, you will see how to track this evolving narrative and what to watch as sentiment around Alector continues...
Wall Street Turns Bullish on HIMS, TDOC and ALEC as Partnerships Reshape Risk Profiles
Three health-technology names are drawing fresh analyst attention this week as strategic partnerships and business pivots reframe the risk-reward calculus for each. Hims & Hers Health (NYSE:HIMS) received two separate upgrades after resolving its legal dispute with Novo Nordisk (NYSE:NVO) through a distribution partnership. Teladoc Health (NYSE:TDOC) earned a Buy from Deutsche Bank on valuation ... Wall Street Turns Bullish on HIMS, TDOC and ALEC as Partnerships Reshape Risk Profiles
Alector (ALEC)'s Technical Outlook is Bright After Key Golden Cross
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
How The Alector (ALEC) Story Is Shifting As Analyst Targets And Sector Views Evolve
Alector’s story on Wall Street has shifted slightly, with one key analyst moving the price target from US$0.75 to US$0.90 while the fair value estimate remains at $2.10. That tweak lines up with fresh commentary that links Alector to a wider group of U.S. small and mid cap biotechs that some expect could gradually move toward funding themselves as big pharma peers approach a patent cliff. As you read on, you will see how this updated target fits into the evolving analyst narrative and what it...
Alector Showcases ABC Brain-Delivery Platform, AL137 and AL050 Updates at TD Cowen Conference
Alector (NASDAQ:ALEC) used a presentation at the 46th Annual TD Cowen Healthcare Conference to highlight progress on its Alector Brain Carrier (ABC) platform, which is designed to deliver multiple therapeutic “cargos” across the blood-brain barrier using the transferrin receptor (TfR). Eric Brown, h